All prices are Manufacturer's Recommended List Value in U.S. dollars. Selecting a distinct grade might outcome in a higher value. The cost you pay at a Baker showroom or authorized dealer may possibly be diverse than the Pedro 5 Piece Dining Table Set By Orren Ellis Manufacturer's Recommended List Price. These rates supersede prior prices and are subject to Pedro 5 Piece Dining Table Set By Orren Ellis adjust without having notice. These rates do not incorporate shipping. Any applicable sales tax and/or VAT will Pedro 5 Piece Dining Table Set By Orren Ellis be added to the prices.
The table is pretty and solid-seeking. We also purchased the bench, so it seats six comfortably with no taking up a lot of unnecessary space. Seats are mainly comfy. The backs are a tiny hard, but that is what you get with pure wood backing. I hope the set lasts a although. Temple & Webster's property delivery service is accessible Australia-wide like Sydney, Melbourne, Brisbane, Adelaide, Perth & Hobart. We also offer you a 30 day no questions asked return policy to assist you Pedro 5 Piece Dining Table Set By Orren Ellis select the best appear for Pedro 5 Piece Dining Table Set By Orren Ellis your house.
Faq & Quation for Pedro 5 Piece Dining Table Set By Orren Ellis ?
Where can I find good Classic Homes furniture ?
How to design a small dining room ?
Why do so many foreigners go to China and think China is good ?
What is a nice simple DIY table ?
What is something that you read recently and is worth sharing ?
Are open kitchens good for Indian homes ?
Dining Room Table Sets & Furniture ?
Why are the seats in bars so high ?
Excellent Pedro 5 Piece Dining Table Set By Orren Ellis. The guidance could possibly be a bit clearer. ?
Sturdy and really good but assembling was a genuine pain! Reading that there were missing holes and centre panel needed to be removed but both aren't accurate. Instructions are puzzling and parts aren't all numbered so you really want to pay attention otherwise you can confuse parts and think that there are missing holes when actually you may be used the wrong part. I am quite make sure you and extension works well, hidden under the other two panels. I would have given 5 stars if the assembling was not so complicated and longer .
Great quality and product for the price! ?
Absolutely love them! They were the perfect height and pop of color my kitchen was requiring! I was truthfully expecting them to be always a little uncomfortable, nonetheless they are amazingly comfy! My hubby was even shocked!
I certainly love this set. The quality is remarkable. This is actually the first furniture assessment I have felt compelled to post! ?
It's a great set and not difficult to assemble. Do note the couch pads atento become screwed directly into the chair framework with no predrilled holes. As well before you purchase get sure to check just about everywhere to get the very best price.


The story of God's plan in action continues through the beginning of Exodus.
God had a plan for Abraham's descendants to inhabit the Promised Land, and Jacob and his family were indeed settled there. But famine struck the region, and God led Jacob and his family down to Egypt where Joseph was in charge of the food supply. The Israelites settled there and prospered for many years.
How did a prospering people become slaves of a foreign ruler?
8 Eventually, a new king came to power in Egypt who knew nothing about Joseph or what he had done. 9 He said to his people, "Look, the people of Israel now outnumber us and are stronger than we are. 10 We must make a plan to keep them from growing even more. If we don't, and if war breaks out, they will join our enemies and fight against us. Then they will escape from the country.
So, in a brutal form of population control, the Egyptian king ordered the Hebrew midwives to kill every boy baby they delivered. Is this not much different than the Chinese authorities who set the "one child" policy in place? Millions of girl babies were either adopted out or aborted so the families could have a boy — with the unfortunate consequence of millions of young Chinese men who can't find a wife because there aren't any women left. I'm guessing from what happened next that the king wanted them to secretly kill the boys…perhaps with a sharp instrument like those used in today's partial birth abortions.
The midwives were more afraid of God than of the king, so they refused to do as he ordered. The baby boys continued to be born, and God gifted the midwives with cleverness so they could defend themselves when questioned by the king about their failure to kill the babies.
Pharaoh turned the Hebrews into slaves and made them suffer with backbreaking work. But the Lord continued to bless the Israelites, and many more Hebrew babies were born despite the cruel slave conditions. Finally, Pharaoh ordered that all Hebrew baby boys be thrown into the Nile River. Can you imagine the heartbreak? The gruesome scene? If someone snatched my girl out of my arms, I would have been tempted to jump in right after her, letting the Nile take me as it took her. I wonder if any women jumped in and saved their children? I sure would have tried!
At any rate, Moses' mother managed to keep him hidden until he was three months old, and then she put him in the Nile. Her son Moses grew up as Pharaoh's adopted grandson — and the Hebrews continued their groaning under the weight of slavery.
If history had been preserved, the course of life as we know it may have been very different. The Egyptians and the Hebrews might have come to some sort of settlement earlier on when the Hebrew population exploded. Perhaps the Hebrews would have moved back to their homeland. Instead, the glory of God was displayed in just the way He planned. He used the ignorance of the people to point the way towards His glory so that even unbelievers would respect him.
It will be interesting as I work my way through the Bible this year to add to this list of the significance of wells in the Scripture. As I do so, I will ponder the significance of the metaphorical wells in my own life.
Very cool introspective of all the well stories we've read so far! I'm sure we'll be seeing many more to come.


I am embarrassed to say that I had this product a long time and just found the paperwork for the review. We have been using this since day one. Once charged it lasts a really long time. It even charges things really fast.
I love that it is so compact, but it is not lightweight. It has been being used around here for about 4 months and it still works great. It has something called a circuit-smart over-charge protection so you do not wreck any tech items. It is backed with a 1 year warranty. It charges 2 devices at once, super-fast.
I have used this up to 10 times to charge things without having to recharge it, so I really like this. The 2 port can charge 2 different items at the same time. It has a micro-USB to USB cable, it is not very long but works great with my laptop. I use the cable to charge the unit then switch it around to charge almost everything else.
As you can see it is slightly bigger than the phone, but it is a lot heavier.
The charge holds for a long time and charges devices fast. Takes about 1 1/2 hours to charge the device from my laptop and then it charges my daughter's and husband's phones in about a half hour completely.
I was given this product to do an honest review only.
Great review, thanks! I am wondering if the device can be charged with a power adapter in a regular wall outlet? You only mentioned charging it with your computer.
Yes it can be charged with a wall adapter.
That would be very useful to have.


text:
Invests in revolutionary
medical device opportunities.
Investing in Medical Innovation
Accuitive Medical Ventures is a venture capital firm with committed capital of $230 million. Our office is located in Atlanta, GA. We're a market driven firm looking for revolutionary medical device technology investment opportunities.
AMV Culture & values
We specialize in two distinct types of investments:
AMV Culture and Values
Our culture is about people, opportunities and experience. We have seen the venture world shift at startling speeds over the last few years, firms with a strong culture and a commitment to value creation —one that paints change as an opportunity to be embraced and not as an insurmountable threat—transform successfully without losing sight of their values.
We value teamwork, our commitment to an investment is a team investment, great wins come from great teamwork, and successful investment results are almost always based on collaborative debate and discussion among the partners.
Our investment approach mirror's our culture and is more than just providing capital. We bring to bear our operational expertise, a focused group of hands-on entrepreneurial experience, we know what separates success from failure. While we assume that anything is possible we base our decisions on strong science, market knowledge, team dynamics and force vigorous debate among the partners before we commit capital.
Partner experience; we believe that our key advantage is the fact we have lived in the trenches, understand the series of challenges that must be solved to reach a successful exit and have the grit to persevere. We expect that our participation will require rolling up our sleeves, digging in with management and together changing the trajectory of the opportunity.
We make a commitment to long-term relationships with entrepreneurs, market analysts, and other venture capitalists building trust and respect such that our relationships will work with us on numerous opportunities.
Collaborative partnership with our portfolio companies and management. We participate in the strategy and goal setting of our portfolio Companies, Board meetings are opportunities to demonstrate our passion and commitment, not a vehicle to gain air miles.
Seizing opportunity, together with management and other Board members, helping our portfolio Companies see opportunity, and help them capitalize on it, this is core to our commitment and a significant element of our value proposition
Our team is focused on being significant investors in a manageable number of superior investments. We target excellent management teams with great ideas based on outstanding science with the potential for developing, delivering and sustaining differentiated value propositions and competitive advantages in creating strategic assets.
The Fund's heritage is based on over 140 years combined experience of our partners in healthcare.
We look for medical device, diagnostic, drug/device and healthcare IT investments where we can use our engineering, regulatory, commercial, financial and operating experience to either help build a world class opportunity or enhance probability of commercial success of our portfolio Companies in delivering superior returns. We take an entrepreneurial approach to investing in opportunistic ideas where our experience suggests our influence can help drive a significant win.
We will not invest in invest in a company's balance sheet and infrastructure or participate in funding during a pivotal clinical trial. We will avoid those later stages where competitive shakeouts and consolidations are inevitable and anticipated growth rates, in our opinion, cannot be sustained, we are not going to consider "tuck-ins" or product extensions.
We have always had high standards for performance, employed creative problem solving, demonstrated passion for success, debated risk/reward as a component of our decision making, and a get the job done philosophy.
The AMV team performs a thorough strategic review of an asset including intellectual property, market, clinical adoption, regulatory, reimbursement and development risks. In assessing risk, AMV looks for opportunities with the following characteristics:
Therapeutic areas with unmet needs, clinical or commercial
Differentiation in product profile to enhance clinical utility
Unique mechanism of action
Ability to create assets with strategic value to potential acquirers
Best-in-class efficacy with a focus on reducing cost and improving process
Potential for establishing new standard of care with a clear path to reimbursement codes or a cash pay model
Good foundational IP at a minimum
Manageable regulatory requirements or a robust strategy for FDA approval
Venture financing for companies with outstanding technology and teams
Venture financing and management of technologies being developed within The Innovation Factory
Accuitive Medical Ventures has a strong relationship with The Innovation Factory (TIF), the successful medical technology serial operating team. TIF has started thirteen companies since 1999 and is based in Atlanta, GA. In conjunction with TIF, Accuitive Medical Ventures has the resources and experience to create long-term value for all medical technology stakeholders.
Accuitive has established relationships with some of the industry's leading institutions to offer emerging companies and investors the opportunity to build unique new businesses and long-term shareholder value. Accuitive's connections to some of the industry's leading practitioners, thought leaders and venture capital firms enable us to add substantial value as investors and board members.
Who we work with:
With the ultimate goal of creating value for our Limited Partners, Accuitive Medical Ventures serves two distinct groups of people:
Working with managment teams
The Firm's approach to working with management teams starts with a basic tenet that having a great, defensible business idea in a scalable market is only one component to attracting our investment commitment. A significant element is having a back-able management team that can execute the plan.
Our philosophy is simple, we don't care about titles, we focus on skill sets. We want to know that the team can carry out the plan they have described; is there the experience, passion, drive and personal character to deliver when confronted with seemingly insurmountable obstacles.
Management teams that are attractive to the Firm include people who not only have the skills to succeed in their business but are also entrepreneurs who are more interested in making money than in running a business for life.
We believe in a well-articulated compensation plan, in many cases we take the lead in establishing the core of an incentive plan (MyoScience, Sebacia, AqueSys, Wave Tec).
A critical element of any compensation plan requires first an understanding of the organizations Vison and Values and what the enterprise value proposition is, this demonstrates managements passion.
If management can't rally the team around a common value proposition, they can't lead the Company to a spectacular exit.
The compensation plan is in place to motivate the portfolio company to focus on their vision and values and to ensure success of the entire organization in delivering their value proposition. The compensation program is designed to provide financial reward using a combination of base salary, target bonus and equity in the form of options all based on achievement of specific performance targets. We want to reward team members for achieving stretch annual goals and to closely align their accomplishments with the interests of the company's shareholders.
We request to be part of the Compensation Committee of the portfolio company.
Passionate, successful teams with strong leadership we can invest in to move exciting technology forward.
creative individuals and groups who would benefit from the business and medical device experience that partnering with The Innovation Factory provides.
What we look for in a partner:
Regardless of whether you're an entrepreneur looking for an investment in your company or an inventor looking to partner with The Innovation Factory, we look for:
Large Target Market
The device or technology must have the potential to serve a large addressable global market.
Strong Intellectual Property
The technology should be novel with robust intellectual property protection.
Benefitical Technology
The technology should create a new treatment modality or represent a substantial improvement.
Compelling Business Model
The technology should have a business model that provides a sustainable advantage.
Clear Path to Market
The technology must have definable regulatory, clinical, and reimbursement (if applicable) paths.
Multiple Exit Opportunities
The technology must fit an area of strategic need for potential acquirers.
How we work with management teams
Portfolio of AMV investments
AMV is a business builder. We partner with entrepreneurs and assist them through the growth stages of their businesses towards an exit.
AMV Portfolio
AcuFocus has developed and is marketing an innovative Intraocular Lens technology to treat presbyopia. AcuFocus was founded within The Innovation Factory.
Coinvestors include Versant Ventures, The Carlyle Group, SV Life Sciences, Sightline, Bausch & Lomb, Medtronic Inc., and Cowen Healthcare Royalty Partners.
AqueSys developed a novel implant to lower intraocular pressure in glaucoma patients. AqueSys was founded within The Innovation Factory.
Coinvestors included SV Life Sciences, The Carlyle Group, Longitude Venture Partners, and RHO Ventures.
Aquesys was acquired by Allergan, Inc.
AxoGen provides surgeons a novel solution to repair and regenerate peripheral nerves.
Axogen is now a public company trading under the ticker symbol AXGN
CardioFocus has developed and is marketing a catheter-based approach to treating atrial fibrillation.
Coinvestors include Oxford Biosciences, SV Life Sciences, H.I.G. Ventures, Aurora Funds, and KBL Healthcare Ventures.
Inogen has commercialized low-weight, portable oxygen concentrators to serve as full-time replacement devices for the home oxygen market.
Coinvestors included Versant Ventures, Novo Ventures, Arboretum Ventures, Avalon Ventures, and Magnetic Moments.
Inogen is a public company trading under the ticker symbol INGN
Intuity Medical is commercializing a novel fully integrated blood glucose monitor for the diabetes market.
Coinvestors include Versant Ventures, USVP, Venrock, IGC, PTV, KCK, Luther and Emergent Medical Partners.
LipoSonix focuses on providing a non-invasive alternative to liposuction surgery using High Intensity Focused Ultrasound (HIFU) technology. LipoSonix was founded within The Innovation Factory and was acquired by Medicis Pharmaceutical Corporation. LipoSonix currently operates within Valeant, Inc.
Coinvestors included Three Arch Partners, Versant Ventures, Delphi Ventures, The Carlyle Group, Essex Woodlands Health Ventures, Pinnacle Ventures, and SV Life Sciences.
MyoScience is developing novel technologies to replace opioids for osteopathic pain relief.
Coinvestors include De Novo Ventures, Nexus Medical, and Saratoga Ventures.
Neuronetics has developed and commercialized a Transcranial Magnetic Stimulation (TMS) system to treat depression. Neuronetics was founded within The Innovation Factory.
Coinvestors include New Leaf Partners, Three Arch Partners, InterWest Partners, ONSET Ventures, Quaker Bioventures, KBL Healthcare Ventures, Investor AB, Polaris Ventures, and Pfizer Ventures.
Nevro is a medical device company developing an implantable device for the treatment of chronic pain.
Coinvestors included Aberdare Ventures, Bay City Capital, Three Arch Partners, MPM Capital, Mayo Medical Ventures and Johnson & Johnson Development Corporation.
Nevro is a public company trading under the ticker symbol NVRO
Respicardia is developing a central Sleep Apnea neurostimulation technology to treat and prevent Congestive Heart Failure.
Coinvestors include Versant Ventures, Three Arch Partners, Polaris Ventures, Affinity Capital, RK Ventures Group, and Abbott Ventures.
Sadra Medical developed minimally invasive alternatives to surgical aortic valve replacement.
Sadra Medical was acquired by Boston Scientific (NYSE: BSX).
Sebacia is developing novel technology to address a large unmet need in Acne Therapy. The company was founded and is currently operating within The Innovation Factory.
Coinvestors include Versant Ventures, Domain Associates, Salem Partners and The Partners Healthcare Innovation Fund.
Softscope developed a disposable accessory for use with existing colonoscopes that makes colonoscopy more comfortable for patients, easier and faster for physicians and potentially eliminate the need for I.V. sedation.
SoftScope was acquired by Fujinon.
Torax Medical has developed and commercialized a minimally invasive reflux management system for the treatment of GERD.
Coinvestors included Thomas, McNerney and Partners, Sanderling Ventures, Mayo Medical Ventures, and Kaiser Permanente.
Torax was acquired by Johnson and Johnson.
WaveTec Vision developed and commercialized a novel wavefront measurement technology that provides on-demand, intraoperative information to cataract and refractive surgeons.
Coinvestors included Versant Ventures, De Novo Ventures, Gund Investments, and Burrill & Company.
WaveTec was acquired by Alcon, a division of Novartis.
AMV Investments News
CardioFocus Press
May 09, 2018 CardioFocus Announces Successful Live Case Featuring HeartLight® X3 System
Breakthrough, Next-Generation Technology for Atrial Fibrillation Showcased at the 21st Annual Prague Workshop on Catheter Ablation
CardioFocus
CardioFocus Announces Successful Live Case Featuring HeartLight® X3 System
MARLBOROUGH, Mass., May 9, 2018 /PRNewswire/ -- CardioFocus, Inc., a medical device innovator and manufacturer dedicated to advancing ablation treatment for cardiac disorders such as atrial fibrillation (AF), today announced a successful live case featuring its breakthrough HeartLight X3 System during the annual Prague Workshop on Catheter Ablation.
Building upon the advanced features of the current HeartLight Endoscopic Ablation System - direct tissue visualization, titratable laser energy, and compliant balloon technology - HeartLight X3 is designed to deliver rapid, continuous, 360-degree lesions, potentially making it the ultimate pulmonary vein isolation (PVI) tool for AF. The system offers a new "RAPID mode". This new mode of operation leverages a precise motor control system that enables uninterrupted, high-speed lesion creation.
The procedure, broadcast live during the workshop, demonstrated the breakthrough potential of the HeartLight X3 system. Successful PVI was achieved with a total energy delivery time of under 20 minutes. Performed by Petr Neužil, MD, PhD, Head of the Department of Cardiology at Na Homolce Hospital in Prague, Czech Republic and Vivek Y. Reddy, MD, Director of Cardiac Electrophysiology and Helmsley Trust Professor of Medicine at The Icahn School of Medicine at Mount Sinai, the case was part of the ongoing clinical evaluation of the HeartLight X3 System.
"The HeartLight X3 System is demonstrating an unprecedented combination of flexibility and speed," said Prof. Neužil "The HeartLight Excalibur Balloon™ enables wide areas of tissue contact outside of the pulmonary veins, allowing for the system's new RAPID mode to create never-seen-before circumferential, transmural lesion sets. RAPID mode allows for titratable, high-power energy delivery that enables fast ablations. The HeartLight X3 System truly holds the potential to be a breakthrough technology in the AF ablation space."
More than 33 million patients worldwide suffer from AF.1 AF, the most common type of cardiac rhythm disorder, prevents blood from being pumped efficiently, which can lead to stroke, weakness, breathlessness, fainting, and a significant reduction in quality of life. PVI with the HeartLight X3 System utilizes laser energy to create lines of scar tissue to block abnormal electrical pathways that cause AF.
The clinical evaluation of the HeartLight X3 System is planned to continue throughout 2018, with regulatory submissions to occur thereafter.
"CardioFocus is dedicated to continuous advancement of its leading AF treatment platform, the HeartLight Endoscopic Ablation System," said Burke T. Barrett, Chief Operating Officer at CardioFocus. "Prof. Neužil and Prof. Reddy demonstrated the remarkable potential of the HeartLight X3 System during the Prague Workshop and I am thrilled with the progress we are making with the ongoing clinical evaluation. We look forward to continuing the study and subsequently establishing our plans for commercial introduction of the HeartLight X3 System."
The HeartLight X3 System is investigational and not available for sale.
May 07, 2018 CardioFocus® Announces FDA Approval Of The Next-Generation HeartLight® Excalibur Balloon™
Designed For The Treatment Of Paroxysmal Atrial Fibrillation*
The Excalibur Balloon leverages the proven universal balloon design of the company's FDA-approved HeartLight® Endoscopic Ablation System and introduces an advanced feature set that optimizes the speed and magnitude of target tissue contact during pulmonary vein isolation (PVI) procedures.
CardioFocus® Announces FDA Approval Of The Next-Generation HeartLight® Excalibur Balloon™ Designed For The Treatment Of Paroxysmal Atrial Fibrillation*
MARLBOROUGH, Mass., May 7, 2018 /PRNewswire/ -- CardioFocus, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted approval for the HeartLight Excalibur Balloon, a next-generation technology designed for the treatment of paroxysmal atrial fibrillation (PAF)*.
More than 2.3 million people in the U.S. suffer from atrial fibrillation (AF), and the numbers are climbing along with the aging population.1 By 2050, AF is expected to affect 15.9 million people.2
"We have seen encouraging results with the Excalibur Balloon. It obtains an impressive antral position and establishes even more tissue contact, which enables contiguous lesion sets," said Vivek Y. Reddy, MD, Director of Cardiac Electrophysiology and Helmsley Trust Professor of Medicine at The Icahn School of Medicine at Mount Sinai. "This is a clear advance in the field of balloon-based AF ablation, delivering on the promise of an ultra-compliant balloon."
In addition to its ultra-compliant design that enables adaptive vein conformance, the Excalibur Balloon also incorporates proprietary Dynamic Response™ technology. This feature allows the user to make real-time adjustments to balloon size, allowing for optimal tissue contact. These combined features are designed to maximize the engagement of the balloon with the pulmonary veins, while decreasing the time required to complete ablation procedures.
"The FDA approval of the Excalibur Balloon is a significant milestone for CardioFocus, as it is the first ultra-compliant balloon introduced into the US market for AF ablation," said Burke T. Barrett, Chief Operating Officer of CardioFocus. "The Excalibur Balloon capitalizes on the existing features of our HeartLight System, which offer an accurate, consistent, and controlled treatment option for PAF patients whose atrial arrhythmias are insufficiently controlled with medication*."
CardioFocus has successfully launched the Excalibur Balloon in Europe following CE Mark approval in September 2017. The technology is now offered at 20 European centers. The company expects to begin a full commercial launch of the Excalibur Balloon in the U.S. in the third quarter of 2018.
1 Go AS, et al. Prevalence of diagnosed atrial fibrillation in adults. JAMA. 2001;285:2370-2375.
2 Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114:119–25.
Intuity Medical Press
Jan 08, 2018 Intuity Medical Obtains $70M in Funding From Existing Investors and Hercules Capital
Financing will fund the commercial launch of Intuity Medical's POGO® Automatic™ Blood Glucose Monitoring System, the first fully-integrated blood glucose monitor
Intuity Medical
Intuity Medical Obtains $70M in Funding From Existing Investors and Hercules Capital
Online Press Release
FREMONT, Calif., Jan. 8, 2018 /PRNewswire/ -- Intuity Medical, Inc., a privately-held company developing innovative technologies for diabetes management, announced today that it has closed $42.5M in the initial tranche of a $70M total round of funding which includes $40M in equity financing from Intuity's existing investors, including Accuitive Medical Ventures, Investor Growth Capital, KCK Group, affiliates of Luther King Capital Management, PTV Healthcare Capital, U.S. Venture Partners and Versant Ventures, plus $30M in debt financing from Hercules Capital.
Intuity's POGO® Automatic™ Blood Glucose Monitoring System, which has received clearance from the U.S. Food and Drug Administration (FDA), is the first blood glucose meter and multi-test cartridge to provide automatic testing with lancing, blood collection and analysis in one easy step without the need for separate strips and lancets. By combining all of the necessary blood glucose testing supplies into a self-contained 10-test cartridge, POGO provides a convenient and discreet solution for millions of patients who need to regularly test their blood glucose in the management of their diabetes.
When combined with Intuity Medical's proprietary Patterns® Diabetes Management System, a secure cloud-based platform for managing glucose information, POGO provides both healthcare professionals and patients a comprehensive shared platform to detect and manage important patterns and trends that impact overall glucose control.
"Our mission is focused on simplifying diabetes management for patients and their care circle," said Emory Anderson, President and CEO, Intuity Medical. "This funding will help strengthen our financial position to commercialize POGO and Patterns in the U.S., thanks to partners like our existing investors and Hercules Capital, who understand our business and support our vision."
Unlike other meters, POGO does not require a patient to use individual test strips or a separate lancing device, which eliminates carrying and disposing of multiple supplies. This means patients can quickly perform a glucose test while on the go or in public settings.
To perform a test, a patient simply presses the POGO test port, and POGO automatically lances the finger, collects a blood sample and displays a result after a four-second countdown. The test only requires a tiny blood sample of 0.25 microliters to analyze the glucose value. After completing 10 tests, the self-contained cartridge can be conveniently disposed of, eliminating the need to handle used test strips and lancets.
"We are pleased to partner with Intuity Medical at this important stage of the company's launch preparation for POGO and Patterns, and to provide growth capital to help the company address the potential market opportunity for POGO," said Scott Bluestein, Chief Investment Officer at Hercules Capital. "This investment in Intuity exemplifies our ability to create flexible and custom financing solutions for innovative Life Sciences companies, helping them achieve important milestones through multiple growth stages of development."
The number of adults with diabetes is a staggering 422 million worldwide, with the disease being the 7th leading cause of death in the U.S. According to the American Diabetes Association, nearly half of the 29 million U.S. patients are not achieving glycemic control in the management of their diabetes. The burdens associated with blood glucose testing are among the reasons for poor glycemic control; many patients cite lack of both simplicity and discretion as barriers to testing with their current meters.
Armentum Partners acted as financial advisor to Intuity Medical in conjunction with the debt financing.
Jan 05, 2017 Intuity Medical Increases Series 3 Funding to $55M With an Additional Close of $15M
The additional financing will help fund the infrastructure build and commercial launch of Intuity Medical's POGO® Automatic™ Blood Glucose Monitoring System, the first fully-integrated blood glucose monitor
Intuity Medical Increases Series 3 Funding to $55M With an Additional Close of $15M
SUNNYVALE, Calif., Jan. 5, 2017 /PRNewswire/ -- Intuity Medical, Inc., a privately-held company developing innovative technologies for diabetes management, announced today that it has closed an additional $15 million, which brings the total Series 3 equity financing for the company to $55 million. KCK Group joins lead investor PTV Healthcare Capital and affiliates of Luther King Capital Management as new investors along with existing investors: Accuitive Medical Ventures, Investor Growth Capital, U.S. Venture Partners, Venrock and Versant Ventures.
Intuity's POGO® Automatic™ Blood Glucose Monitoring System, which received clearance from the U.S. Food and Drug Administration (FDA) in April 2016, is the first blood glucose meter and multi-test cartridge to provide automatic testing with lancing, blood collection and analysis in one easy step without the need for separate strips and lancets. By combining all of the necessary blood glucose testing supplies into a self-contained 10-test cartridge, POGO provides a convenient and discreet solution for millions of patients who need to regularly test their blood glucose in the management of their diabetes.
The number of adults with diabetes is a staggering 422 million worldwide, with the disease being the 7th leading cause of death in the U.S. According to the American Diabetes Association, nearly half of the 29 million U.S. patients are not achieving glycemic control in the management of their diabetes. The burdens associated with blood glucose testing are among the reasons for poor glycemic control; many patients cite lack of both simplicity and discretion as barriers to testing with their current meter. Unlike other meters, POGO does not require a patient to use individual test strips or a separate lancing device, which eliminates carrying and disposing of multiple supplies. This means patients can quickly perform a glucose test while on the go or in public settings.
"The additional funding will help further our commercialization efforts in bringing POGO Automatic to the U.S. market for patients who have been looking for a convenient way to test their glucose," commented Emory Anderson, President and CEO, Intuity Medical, Inc.
Respicardia Press
Jan 08, 2018 Respicardia Announces First U.S. Commercial Case With The remedē® System
Industry Veteran Peter Sommerness Joins as CEO to Lead U.S. Launch
Respicardia
Respicardia Announces First U.S. Commercial Case With The remedē® System
MINNETONKA, Minn., Feb. 2, 2018 /PRNewswire/ -- Respicardia, Inc., a medical technology company developing innovative therapies that improve cardiovascular health, announced today that the first U.S. commercial case using the remedē® System to treat central sleep apnea was completed at The Ohio State University Wexner Medical Center in Columbus, Ohio by Ralph Augostini, MD, FACC, FHRS, Bob and Corrine Frick Chair in Cardiac Electrophysiology, Associate Professor of Medicine and co-director of the electrophysiology training program. The first case coincides with the naming of seasoned medical device executive, Peter Sommerness, as CEO of Respicardia and leader of the remedē System U.S. launch.
"The remedē System is a breakthrough technology that uniquely treats central sleep apnea while greatly improving a patient's quality of life," stated Dr. Augostini. "I am proud to be a part of the system's first U.S. commercial case that has the potential to become the standard of care for these patients."
Central Sleep Apnea (CSA) is a serious breathing disorder that disrupts the normal breathing pattern during sleep and negatively affects quality of life and overall cardiovascular health. CSA results from the brain's inability to send appropriate signals to the respiratory muscles to stimulate breathing. The remedē System is clinically proven to safely and effectively treat moderate to severe CSA in adult patients and improve quality of life.
"Central sleep apnea is very common in cardiac patients, especially patients with heart failure, and is associated with a significantly greater risk for morbidity and mortality," explained William Abraham, MD, Professor of Internal Medicine and Chief of the Division of Cardiovascular Medicine at The Ohio State University Wexner Medical Center. "Being able to treat CSA offers a new hope to improve the quality of life for my patients."
In addition to its first U.S. commercial implant, Respicardia announces today that it has appointed Peter Sommerness as CEO. Mr. Sommerness brings 20 years of commercial and operational experience from the electrophysiology and cardiac rhythm management markets. Most recently, Mr. Sommerness was a Partner at McKinsey and Company, where he was a leader in the global medical device practice, focusing on commercialization strategies, product launches, and operational improvement initiatives. Prior to this, he held the role of General Manager and Vice President of Cardiac Electrophysiology at Boston Scientific, where he was responsible for business unit strategy, portfolio and commercial execution.
"I'm excited to join Respicardia and its seasoned team at such a pivotal moment," stated Mr. Sommerness. "With the major milestone of our first U.S. commercial implant, I look forward to building on this momentum in the U.S. market and to bringing this groundbreaking technology to patients suffering from the harmful effects of central sleep apnea."
About the remedē® System
The remedē System is a transvenous implantable neurostimulation system that stimulates the phrenic nerve, and engages the diaphragm to restore a normal breathing pattern during sleep in patients with CSA. The remedē System pivotal trial, published in The Lancet, demonstrated that transvenous neurostimulation with the remedē System can significantly reduce the severity of CSA, improve sleep, quality of life and patient satisfaction.
The remedē System received U.S. Food and Drug Administration (FDA) approval in October of 2017 and is commencing market release of the system in the United States.
Dec 18, 2017 Respicardia Closes $58.5 Million In Financing To Treat Central Sleep Apnea
Company announces strategic relationship with ZOLL Medical
Respicardia Closes $58.5 Million In Financing To Treat Central Sleep Apnea
MINNETONKA, Minn., Dec. 18, 2017 /PRNewswire/ -- Respicardia, Inc., a private medical technology company, announced today that the company has closed a $58.5 million financing, led by ZOLL Medical Corporation, a leading manufacturer of medical devices and related software solutions. All of Respicardia's existing major investors helped to complete the financing round.
"We believe the remedē® System will soon become the treatment of choice for patients suffering from central sleep apnea and are pleased to receive significant funding from ZOLL in support of this important mission," stated Bonnie Labosky, President and CEO of Respicardia. "Proceeds from the financing will be used to fund our U.S. commercialization efforts and support ongoing development of the system."
"The remedē System is a breakthrough technology that uniquely treats the devastating effects CSA has on a person's quality of life and cardiovascular health," explained Jonathan A. Rennert, CEO of ZOLL. "This investment in Respicardia exemplifies ZOLL's commitment to advance novel therapies, especially those that address heart failure or one of its many co-morbidities such as central sleep apnea."
Oct 10, 2017 Respicardia's remedē® System Receives FDA Approval
Breakthrough Treatment of Moderate to Severe Central Sleep Apnea in Adult Patients Now Available
Respicardia's remedē® System Receives FDA Approval
MINNETONKA, Minn., Oct. 10, 2017 /PRNewswire/ -- Respicardia, Inc., a private medical technology company, announced today that it received U.S. Food and Drug Administration (FDA) approval of its remedē® System, a transvenous implantable neurostimulation system that stimulates the phrenic nerve, and engages the diaphragm to restore natural breathing during sleep in patients with central sleep apnea (CSA). The regulatory approval was based on findings from the remedē System pivotal trial, which demonstrated that transvenous neurostimulation with the remedē System can significantly reduce the severity of CSA, improve sleep, quality of life and patient satisfaction. The data from the pivotal trial were published in The Lancet in September 2016.
The remedē System is indicated for the treatment of moderate to severe CSA in adult patients. CSA is a serious breathing disorder that disrupts the normal breathing pattern during sleep and negatively affects quality of life and overall cardiovascular health. CSA results from the brain's inability to send appropriate signals to the respiratory muscles to stimulate breathing.
"We are thrilled the remedē System received FDA approval and are excited to provide this safe and effective therapy that is proven to improve the quality of life for CSA patients," said Bonnie Labosky, President and CEO of Respicardia. "This is a significant step forward in our efforts to offer clinicians a breakthrough and effective treatment option for their patients with CSA."
Current treatment options are limited and there is a large unmet need. The remedē System's novel approach to treating CSA is a physiologic treatment that creates negative pressure to move air into the lungs, similar to normal breathing. The system initiates therapy automatically and continues throughout the night without the need for a patient to apply any external equipment.
"The patients at our center treated with the remedē System experienced outstanding results and significant reduction in their CSA symptoms," said Maria Rosa Costanzo, MD, Principal Investigator of the remedē System Pivotal Trial. "Having a therapeutic option for patients with CSA that automatically provides therapy and works throughout the night is a breakthrough treatment for this serious breathing disorder."
In the remedē System pivotal trial, 96% of patients were highly satisfied with their therapy. The company plans on an initial limited release that will progress to broader market commercialization.
About the remedē System Pivotal Trial The remedē System Pivotal Trial, a prospective, multicenter, randomized controlled trial, evaluated the safety and effectiveness of transvenous phrenic nerve stimulation using the remedē System in patients with moderate to severe CSA. The primary effectiveness outcome was a comparison of the proportion of patients in the treatment versus control groups achieving a reduction in apnea-hypopnea index (AHI) of 50 percent or greater from baseline to 6 months. Clinical investigators at 31 sites in the United States and Europe implanted the remedē System in 151 patients and randomized them 1:1 to the treatment or control group. The trial met its primary endpoint for efficacy. In the modified intention-to-treat population, significantly more patients in the treatment group achieved 50 percent or greater reduction in AHI from baseline to 6 months than those in the control group with a clinically meaningful difference of 41% (p<0.0001). Additionally, the 12-month freedom from serious adverse events related to the implant procedure, remedē System or delivered therapy was 91 percent.
Sebacia Press
May 07, 2018 Sebacia Announces Favorable Ruling by U.S. Court of Appeals for the Federal Circuit Regarding Patent Interference Proceedings with Sienna Biopharmaceuticals, Inc.
The ruling relates to a patent interference proceeding between The General Hospital Corporation (GHC, the owner of certain patents licensed by Sebacia) and Sienna Biopharmaceuticals, Inc.
Sebacia
Sebacia Announces Favorable Ruling by U.S. Court of Appeals for the Federal Circuit Regarding Patent Interference Proceedings with Sienna Biopharmaceuticals, Inc.
DULUTH, Ga., May 7, 2018 /PRNewswire/ -- Sebacia, Inc., a privately held dermatology and aesthetics company, today announced a precedential ruling from the U.S. Court of Appeals for the Federal Circuit. The ruling relates to a patent interference proceeding between The General Hospital Corporation (GHC, the owner of certain patents licensed by Sebacia) and Sienna Biopharmaceuticals, Inc. The Federal Circuit ruled in favor of GHC deciding that the Patent Trial and Appeal Board (PTAB) was arbitrary and capricious in terminating a patent interference proceeding initiated at GHC's suggestion concerning Sienna's Patent No. 8,812,941. The Federal Circuit remanded the interference proceeding for the PTAB to determine who between GHC and Sienna was the first to invent the subject matter covered by Claim 1 of the patent.
Anthony Lando, CEO of Sebacia, commented, "We are pleased with the outcome of this precedential decision by the Federal Circuit, and we look forward to further proceedings within the PTAB focused on determining first to invent."
The referenced case is General Hospital Corp. v. Sienna Biopharmaceuticals Inc., case number 17-1012, in the U.S. Court of Appeals for the Federal Circuit.
May 07, 2018 Sebacia Announces $36 Million Equity and Debt Financing to Advance Breakthrough In-Office Procedure for Acne
the company has completed a $20 million Series D financing led by existing investors Versant Ventures, Domain Associates, Accuitive Medical Ventures and Partners Healthcare Innovation Fund
Sebacia Announces $36 Million Equity and Debt Financing to Advance Breakthrough In-Office Procedure for Acne
DULUTH, Ga., July 25, 2017 /PRNewswire/ -- Sebacia, Inc., a privately held, clinical and commercial stage dermatology and aesthetics company, today announced that the company has completed a $20 million Series D financing led by existing investors Versant Ventures, Domain Associates, Accuitive Medical Ventures and Partners Healthcare Innovation Fund. New investors accounted for approximately 60 percent of the round and include Salem Partners and other undisclosed investors. Additionally, Sebacia closed a $16 million debt facility with Hercules Capital.
"At this pivotal time, we are grateful for the continued support of our top-tier venture capital syndicate and energized by the addition of Salem Partners and other new investors," said Anthony V. Lando, Sebacia's Chief Executive Officer. "From intellectual property to extensive clinical experience and a defined clinical path to approval, we believe we have all the pieces to bring Sebacia's breakthrough treatment for acne to market in Europe and the United States."
John Dyett of Salem Partners said, "We have been very impressed by the Sebacia team and are excited to join such a distinguished group of institutional life sciences investors."
Sebacia is developing a proprietary microparticle treatment for moderate to severe acne. Sebacia's microparticles are delivered in a topical suspension specifically designed to work with hair removal or pigmented lesion treatment laser systems, which are already owned by the dermatologist. The Sebacia treatment is intended to be a simple, physician-guided, in-office procedure that could provide an alternative to existing therapies, such as oral antibiotics and isotretinoin. Sebacia has extensive clinical experience with nearly 2,000 treatments performed to date. The procedure is CE Marked in Europe and is being evaluated in clinical studies in the United States.
Sebacia intends to use the proceeds from the financing to complete a U.S. pivotal trial with expected results reporting by mid-2018, with submission and FDA response expected by the end of 2018. Further, with CE mark and market clearance for commercialization in Europe, Sebacia also intends to expand its commercial presence in the European Union. Additionally, the company plans to expand its worldwide patent estate, which includes the seminal selective photothermalysis methods developed by Dr. R. Rox Anderson at Massachusetts General Hospital.
Torax Medical
Feb 17, 2017 Ethicon Announces Agreement to Acquire Torax Medical, Inc.
Torax Medical offers an innovative technology for the treatment of Gastroesophageal Reflux Disease (GERD)
Ethicon Announces Agreement to Acquire Torax Medical, Inc.
CINCINNATI, Feb. 17, 2017 /PRNewswire/ -- Ethicon, Inc. today announced a definitive agreement to acquire Torax Medical, Inc., a privately held medical device company that manufactures and markets the LINX® Reflux Management System, a novel minimally invasive device for the surgical treatment of GERD. The acquisition of Torax Medical will enable Ethicon to offer patients a safe and effective alternative to the anatomy-altering laparoscopic Nissen fundoplication surgical procedure.1
This LINX® Reflux Management System is a small implant comprised of interlinked titanium beads with magnetic cores which augment the body's natural barrier function to prevent reflux. LINX is currently used by physicians in over 300 hospitals in the United States and Europe. This acquisition is consistent with Ethicon's strategy of advancing innovation and investing in areas of unmet medical needs such as esophageal health.
Financial terms of the transaction have not been disclosed. The closing of the transaction is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act and other customary closing conditions. The transaction is expected to close during the first quarter of 2017.
About Ethicon From creating the first sutures to revolutionizing surgery with minimally invasive procedures, Ethicon, part of the Johnson & Johnson Medical Devices Companies, has made significant contributions to surgery for more than 60 years. Our continuing dedication to Shape the Future of Surgery is built on our commitment to help address the world's most pressing health care issues, and improve and save more lives. Through Ethicon's surgical technologies and solutions including sutures, staplers, energy devices, trocars and hemostats and our commitment to treating serious medical conditions like obesity and cancer worldwide, we deliver innovation to make a life-changing impact. Learn more at www.ethicon.com, and follow us on Twitter @Ethicon. Ethicon represents the products and services of Ethicon, Inc. (the signing party), Ethicon Endo-Surgery, Inc. and certain of their affiliates. 1 Riegler, et al., Surg Endosc. (2015) 29:1123-1129
The AMV Team
Operating executives with more than 15 years of investment experience from inception to liquidity in the Healthcare Venture/Growth sector
The team's operating experience guides portfolio investments to:
Identify and Resolve technical challenges
Target markets that are primed for disruption
Drive commercial adoption
Quickly replace ineffectual key employees
Be capital efficient
Team has been together for over a dozen years, and is seasoned, stable, and has a proven track record
Extensive Hands on experience with:
Identifying key market opportunities for novel medical devices
FDA, preparing submissions and responses, panelss
Clinical trial design and management
Commercializations
Thomas D. Weldon
Chairman,
Charles E. Larsen
Gordon T. Wyatt
Cory S. Anderson
Anthony V. Lando
Contact Accuitive Medical Ventures
If your business or technology is ready to partner with AMV, please submit your business plan for review.
charlie@amvpartners.com
295 Premiere Parkway, Suite 100
Atlanta, Ga 30097 USA
Chairman, Managing Director
Tom has been a pioneer in health care for three decades and holds 30 U.S. patents for medical devices.
Mr. Weldon's expertise is envisioning new market opportunities, driving businesses to become more successful and getting them to a liquidity event. He has cofounded more than a dozen companies including: Novoste, AcuFocus, AqueSys, LipoSonix, and Neuronetics, which in total have created more than $2 billion in shareholder value.
In addition, Tom has served on the board of numerous private companies, Universities and Foundations including Respicardia, Mednova and MyoScience. Today, he is the founder, chairman and CEO of Ponce De Leon Pharmaceuticals, which focuses on increasing human health span. He also serves as Chairman of The Innovation Factory — a medical device incubator, and Chairman and Managing Director of Accuitive Medical Ventures, a venture capital fund with over $230M of AUM.
Prior to his current position, Mr. Weldon was a cofounder, CEO and chairman of Novoste Corporation, where he grew the business from its inception through its IPO with a peak market cap of $1.2B.
Mr. Weldon is a frequently interviewed expert for his industry and has been written about multiple times by Inc. Magazine. In addition, he has spoken for: JPMorgan, Piper Jaffray, Robertson Stephens, Cowen & Co and MedTech Strategist Conferences
Tom holds a B.S. in Industrial Engineering from Purdue University and an M.B.A. in Operations and Systems Management from Indiana University. He has received numerous awards including:
The Distinguished Engineer Alumni Award (Purdue) ,The Outstanding Industrial Engineer Award (Purdue), The Burton Morgan Entrepreneurship Award, The Junior Achievement IMPACT Award
Tom volunteers his time as an Advisory Board member for the Buck Institute for Research on Aging and the Purdue University Weldon School of Biomedical Engineering.
As co-founder of Accuitive Medical Ventures, Charlie brings nearly 40 years of operating experience, as well as expansive research and technical experience in the medical device industry. Charlie currently serves as a board member for CardioFocus. He is also a board observer at Intuity and AcuFocus. He currently is an Independent director at Femasys, a commercial stage company in the Feminine Healthcare space.
Charlie co-founded The Innovation Factory and serves as its Vice Chairman, co-founding numerous companies including: Cerebral Vascular Applications, Neuronetics, AcuFocus, , LipoSonix, NeoVista, Cellutions, Novalign, AqueSys, Halscion, and Sebacia.
Charlie was co-founder of Novoste Puerto Rico, along with Tom Weldon, where his efforts as a director and executive were critical to its ultimate success and sale to NAMIC, a division of Angiodynamics. He was subsequently a co-founder at Novoste Corporation, a vascular brachytherapy solution to restenosis, ultimately acquired by Best Medical.
Before forming Novoste, Charlie held positions with Cordis Corporation, Key Pharmaceuticals and Parke-Davis/Warner Lambert in executive, senior engineering and project management roles. Prior to several years in pharmaceutical design and manufacturing, he held various roles in the petrochemical and nuclear power industries.
Charlie received a B.S. in Mechanical Engineering from the New Jersey Institute of Technology. He attended Kenan Flagler at the University of North Carolina for Management Technology.
He holds over 30 issued U.S. and various International patents on medical devices and processes.
As CFO of Accuitive Medical Ventures, Gordy brings nearly 40 years of financial and operating experience, with seventeen years in the medical device industry. Gordy also serves as CFO of The Innovation Factory (TIF).
Gordy's industry experience covers entrepreneurial and mature businesses ranging from pre-revenue start-up to $2.0 billion revenue market leader, spanning high technology, internet and E-commerce, EDI, life sciences, private equity, manufacturing, distribution, advertising, publishing, and consulting services. Extensive European exposure with premier global companies.
Developed financial organization and support system for TIF, TIF portfolio companies, and AMV's venture capital fund with $230 million under management. Served as CFO for all TIF portfolio companies during founding and initial star-up stage, including: Cerebral Vascular Applications, LipoSonix, Neuronetics, AcuFocus, NeoVista, Cellutions, Novalign, AqueSys, Halscion, and Sebacia. Managed all finance and administration for AMV, and for TIF and TIF portfolio companies through their founding and early development stage.
Prior to joining TIF and AMV, Gordy was a proven senior leader at General Electric Company, Dun & Bradstreet Corporation, and WebMD Corporation, with experience in start-up, turnaround, and high growth business environments. His success in those companies reflects his strong financial and operational perspective and experience in business planning and day-to-day finance and business operations.
Throughout his career, he has been responsible for all financial and accounting operations including accounting, budgeting, management reporting, operational analysis, business unit support, and integration activities for acquired businesses. In various roles throughout his career, he has also had responsibilities for customer service, HR and IT activities.
Gordy received a B.S. with a double major in Accounting and Finance from Lehigh University. During his tenure at GE, he participated in many development programs, including GE's Financial Management Program, Business Management and Advanced Marketing Management Programs, and Executive Development Program.
Cory is a Principal with Accuitive Medical Ventures and VP Clinical Marketing and Business Development for Sebacia (a TIF-founded company). Cory is currently a board observer for Myoscience.
Cory was the Program Manager for AqueSys from its inception through its transition out of TIF. Following the transition to permanent management, Cory remained involved with the company as a board observer until its exit to Allergan in 2015. For AqueSys, Cory managed the transformation of an academic invention into a product and through its initial clinical studies internationally. In his role with AqueSys, Cory met with FDA, grew the company's patent portfolio, and eventually successfully transitioned the company to a management team focused on positioning AqueSys for FDA approval and commercial launch.
Cory has experience in conducting investor due diligence in multiple disease states across multiple technologies. He has successfully raised equity and debt financing for portfolio companies. Cory has been responsible for vetting new investment opportunities for AMV and building business plans for new TIF companies.
Operationally, Cory has experience in new product development of medical technologies, designing and conducting clinical studies worldwide, commercially launching products in Europe, developing regulatory strategies, and managing intellectual property portfolios.
Cory joined TIF from Novoste Corporation where he was a Product Manager focusing on new growth opportunities in addition to holding various positions of increasing responsibility within R&D.
Cory is an author of 2 published papers and 1 book chapter and is an inventor on 7 issued US patents and additional pending applications.
Cory holds a B.S. and M.S. in Biomedical Engineering from Tulane University and an M.B.A. from Emory University.
Anthony is Chief Executive Officer of The Innovation Factory (TIF) since 2005 and co-founder and CEO of Sebacia since 2010. Prior to TIF Anthony served as Chief Operating Officer of BTG plc, a UK public-listed specialty pharmaceutical company. Anthony has managed successful AMV investments in and served on the boards of AqueSys Inc. (co-founder, Board member since 2009, sold to Allergan; $725M Ophthalmology Device), Wave Tec Vision® ( Board Member, WaveTec Vision Inc. 2013-2014, sold to Alcon, Inc.; $350M Ophthalmology Device), Board Member, Myoscience Inc. 2013-Present Orthopaedic Device), and Halscion Inc (keloid scar treatment). At BTG plc. Anthony was responsible for BTG's global business in the commercialization of Life Science (Ageing, Oncology and Neurosciences), IT and Engineering (Telecoms/Semiconductor) and Healthcare (Medical Device) technologies.
Anthony has experience in strategy development and operational management, a track record of achievement in developing and introducing technologies to physical and life science markets.
In 1997 Anthony helped established a technology venture company (Primaxis Technology Ventures) in partnership with the Royal Bank of Canada. As the BTG member of the Primaxis Board and Investment Committee he participated in deploying over $100M. Investments included Spotwave Wireless, Silicon Optix and Meriton Networks.
During Anthony's tenure at BTG plc, he was responsible for expanding the market position for life science clinical development programs. Building a pipeline of over 10 compounds in lead identification, pre-clinical, IND or Phase I development activities. Anthony also lead the activities for medical device clearance EU approval and IDE.
Anthony's experience includes operations, product development, intellectual property management, financial management, and fundraising for both public and private companies, as well as development and creation of technology-based entities.
Prior positions include engineering and marketing roles with Philips Medical Systems and Stone & Webster Engineering.

redpajama_set_name: RedPajamaCommonCrawl


Discussion in 'Performance' started by billz, Jun 2, 2013.
Read that last night Bill makes you not want to start your zed after reading what happened. Are you doing yours as a matter of course ?
Suppose i'll have to do mine .
Does anyone know if my 2.0 M52 engine has one as its got to be worth replacing if it has.
If the zed was made after 1998 then yes it will have one. That was when the M52 engine came out.
Many thanks for that best I find and order one.
Reading through the thread on .net there is a comment which states they were fitted from Sept (?) 1998 - do you agree?
I've checked back to march 96 and the unit is listed as fitted, looking at compatibility it was used on all variants of the M44 even on the 318is and the M43 during 94 / 95 but most of those will be LHD cars.
I just looked on YouTube and its fairly easy to replace (two torx bolts and one electrical connection). Simples !!


Schnecken on the run » Blog Archiv » Let´s go home…gehen wir nach Hause.
Let´s go home…gehen wir nach Hause.
We were in Sao Paulo, it was travel day 307 and two days before our flight back to Germany and Austria, when I wrote an article about our "going home". Whitney and I talked a lot in those days about our feelings about the ending of our trip. We talked about things we have seen and done in the last year, we talked about what we gained, what we missed, some resolutions and on and on… We were looking forward to the exciting things we had planned for the upcoming weeks.
Well, back home, it is sometimes easy to loose some memories and to "forget" those thoughts and resolutions. It has always been my wish to finish the article that I had started writing earlier. Reading it now, I realize that I don´t want to change it anymore, I just want to put it online like it is.
It has been three months since we have returned from our round the world trip. Our time has been filled with exciting moments, friends and family from Canada visited and we had a beautiful time with our wedding in Denmark. We still did not find (or take) a lot of time to look back at our pictures, but I know the time will come and all those great memories will never be forgotten.
Whitney had the idea of calling our blog "Schnecken-on-the-run". She said that we are like "Schnecken" (snails), we are slowly moving around the world, carrying our little hut with all our belongings on our back. And then we remembered the picture we had taken of us two years ago on a canadian highway and found that it fits perfectly as the name of our website. We put it into the header of our website and with some help from a friend our blog was created.
In the last year we have visited 16 different countries, touched 4 continents and probably slept in around 140 different places. We used all sorts of transportation, took around 30 flights, spent days in busses, trains and cars. We walked many days through cities and villages and there were plenty of long hikes with our backpacks. We enjoyed the variety. Whether it was hiking or camping in the high mountains of Nepal, Argentina or Peru, sunbathing at the greatest beaches in Thailand, Malaysia or Brazil, fine dining in Lima, Valparaiso, Buenos Aires or Sao Paulo, street food all around the globe. Meeting and visiting old and new friends and finding new family. We were able to see their city, enjoy time together and simply find a home away from home for a couple of days. Filling up our Diving Log book with some of the best spots in the world, seeing infamous animals under and above the water on the coastline or in the jungel of Borneo. Being cultural and following the paths of ancient societies in Cambodia, Indonesia or Peru. Staying in hotels, hostels, on someones couch, a tent, a car or ultra romantic lodges…it all has its good side!
We started and finished our trip with highlights. The Anapurna Circuit in Nepal at the beginning, meeting my brazilian family at the end and inbetween were several special events and memories on route from Asia to Southamerica.
Today is day 307 of our tour around the world. Now the "Schnecken" will go back to Europe…but before we finally go home, we´ll go with lots of friends to a fun and traditional ski trip to Austria for 10 days. I think that it a very nice ending. From there, Whitney will move to Canada for a couple of weeks. When she returns to Hamburg, her family and some canadian friends will follow and join us for our next personal adventure…our wedding in Denmark at the end of april. Followed by some quality time with our canadian and german family and friends in and around Hamburg and a small tour through Germany. Then it is finally time to completely unpack our packs, settle (a bit) and enjoy our home.
Now we go home or "Gehen wir nach Hause", as my brazilian family says to each other (who by the way do not speak german) on late night out. There are very exciting things to come and I am looking forward to the evenings when Whitney and I will look at our pictures, the travel map and read some of our articles. It will bring back great memories of the time we spent together around the world and it will remind us of some things we gained together and some resolutions that we have conquered together..
It is funny to read this now, three months later. We still have not really had the time to look at our pictures or to finish some videos. But this will come. Now it is time for us to get "TRAVEL" excited again: The Schnecken will slide on. We are about to leave for another trip, together with two close german friends (a couple who is as well newly married). We will explore Canadas West with its Rodeo and Rockies and the western coast of the USA will be our destination. Two more weeks and we will start packing our little huts (-; Let´s go, yee HA!


We accept - direct billing, aaa rates, aarp and extended stay rates for payment.Our products and services include - business center, - continental breakfast, - direct billing, - fitness center, - hi- speed internet (wireless or cable), - indoor pool spa, - micro- fridge, iron, coffee maker, hair dryer in all rooms, - three queen bedrooms, - two room suite with 1 king or 2 queens, 100% non-smoking property, 100% satisfaction guaranteed, 101 rooms catering to business executive, 2 room & extended suites, 24 hour pool- sauna- spa & fitness center, 24 hour restaurant, 24 hour shuttle, 25" remote cable tv, 27" color tv, 6 restaurants nearby, 92 guest rooms with 32 new suites, am fm clock radio, ample free parking, at&t free local calls, available in every room at the la quinta inn of ardmore, banquet & meeting facilities for groups up to 200, banquet & meeting room facilities, beach resort, beachfront pool, business fitness center, coffee maker, fridge, microwave, and hair dryer in all rooms, coffee makers, coin operated laundry, complimentary deluxe continental breakfast, conference rooms, continental deluxe breakfast, corporate rates available, data port, data port phones & free local calls, dataport phones, delux continental breakfast, deluxe continental breakfast bar, deluxe hot breakfast bar, double & king rooms, double occupancy. not valid with other discounts., dry cleaning/laundry, electronic door locks, exercise room, expanded cable channels, family rooms, fax & photocopy service, fitness ctr., fitness facility, fitness facility with sauna and steam room, fitness room, for reservations call, free airport shuttle, free breakfast, free breakfast buffet with fresh waffles, free complimentary breakfast, free continental breakfast, free high speed internet access, free high-speed internet, free high- speed internet access in all rooms, free high- speed internet in all rooms, free wireless internet, fully equipped fitness center, great rooms free breakfast affordable rates, guest laundry, guest laundry facilities, guest laundry facility, guest laundry, in- room iron board, hairdryer, hbo, hbo, encore, heated outdoor pool, heated pool & spa, heated pool (seasonal), heated spa, heated spa & outdoor swimming pool, hi- speed internet wireless or cable, high speed wireless internet, highspeed internet, hospitals, churches, restaurants, and university nearby, hot tub, in room high speed internet, in-room coffee, in-room coffeemaker, in-room drip coffeemaker, in-room hair dryer, in-room iron & ironing board, in- room iron and full- size ironing board, in-room microwave, in-room on demand movies, in-room refrigerator, indoor heated pool & spa, indoor heated pool w hot tub, indoor pool & spa, indoor pool, fitness center, business center, indoor swimming pool, indoor swimming pool & spa, indoor whirlpool, inn & suites, inns, interior corridors, ironing board & iron, irons board & hairdryers, jacuzzi, jacuzzi suites, jacuzzi suites available, meeting room available, meeting rooms, meeting space, micro-fridge, micro- frige, iron, coffee maker, hair dryer in all rooms, microwave & refrigerator, microwave & refrigerator in every room, microwave & refrigerators, microwave & refrigerators available, microwave refrigerator in all rooms, nationwide reservation service, nationwide reservations service, new all suite motel, newly remodeled, newly renovated, non-smoking rooms, olympic size heated pool, on-site laundromat, other fine services available, outdoor heated pool, outdoor pool and spa, pet friendly, pets accepted, pets welcome, plus special rates for aaa and aarp members, pool, sauna, steam room, spa and fitness room, refrigerator & microwave, returns, room service, security cameras, senior specials, ski & golf packages, suites with whirlpool, themed, spa, family & kitchenette suites, two room suites with 1 king or 2 queen, voice mail, wheelchair accessible and wireless high speed internet now available.Certifications/affiliations: aaa approved.Brands: aarp, hbo, high speed internet, jacuzzi, jacuzzi suites, la quinta inn & suites, la quinta inns and la quinta inns & suites.
If you have used the services of La Quinta Inn Suites Phoenix Mesa East we'd love to hear from you! Use the form below to review and comment on your experience.


Are Traditional Wedding Receptions a Thing of the Past?
How important is holding onto tradition in a wedding reception today? We explore the history of this cherished events and how it continues to change.
Gone are the days of stoic wedding pictures. Michael A. Anderson, photographer for CM and wedding photographer as well, shares some of his funniest pics over the years!
A typical honeymoon destination will be something like; a cruise, a tropical destination or a luxurious resort. This article is not for typical people.
This month we explore how weddings have changed, have some fun with wedding photos and explore some off-the-beaten-path honeymoon destinations in NC!
Cabarrus County wanna-be pilots are fortunate enough to have Concord-Padgett Regional Airport close by and home to a number of flight schools.


text:
Earl of Durham ist ein erblicher britischer Adelstitel in der Peerage of the United Kingdom.

Familiensitz der Earls ist Biddick Hall auf dem Anwesen Lambton Park bei Chester-le-Street im County Durham.

Verleihung und Geschichte des Titels

Der Titel wurde am 23. März 1833 an den britischen Staatsmann der Whig-Partei John George Lambton, 1. Baron Durham, verliehen. Dieser wurde 1838 Generalgouverneur von Britisch-Nordamerika. Zusammen mit der Earlswürde wurde ihm der nachgeordnete Titel eines Viscount Lambton verliehen, der vom Heir Apparent als Höflichkeitstitel geführt wird. Bereits am 29. Januar 1828 war dem ersten Earl der fortan ebenfalls anachgeordnete Titel Baron Durham, of the City of Durham and of Lambton Castle in the County Palatine of Durham, verliehen worden. Alle drei Titel gehören zur Peerage of the United Kingdom.

Nachdem der 6. Earl of Durham seinen Titel am 24. Februar 1970 ablegte, um weiter Mitglied des House of Commons und parlamentarischer Unterstaatssekretär im Verteidigungsministerium zu bleiben, ruhte der Titel bis 2006. Während dieses Zeitraums benutzte der spätere 7. Earl, den Höflichkeitstitel Lord Durham.

Earls of Durham (1833)
 John Lambton, 1. Earl of Durham (1792–1840)
 George Lambton, 2. Earl of Durham (1828–1879)
 John Lambton, 3. Earl of Durham (1855–1928)
 Frederick Lambton, 4. Earl of Durham (1855–1929)
 John Frederick Lambton, 5. Earl of Durham (1884–1970)
 Antony Lambton, 6. Earl of Durham (1922–2006), (Titelverzicht 1970)
 Edward Lambton, 7. Earl of Durham (* 1961)

Titelerbe (Heir Apparent) ist der Sohn des derzeitigen Earls, Frederick Lambton, Viscount Lambton (* 1985)

Weblinks
 Durham, Earl of (UK, 1833) bei Cracroft's Peerage
 Leigh Rayment′s Peerage Page

Durham

Erstverleihung 1833

redpajama_set_name: RedPajamaWikipedia


text:
Trafalgar House in Winchester city centre is fully occupied after a £3 million refurbishment through owner Gentian.
One of Winchester's most prominent buildings is to be fully occupied for the first time in nearly a decade after a £3 million refurbishment. Major construction firm Skanska has signed a 20-year lease on 15,000 sq ft of office space in the part-Grade II listed city centre Trafalgar House.
Gentian Development Group, which completed major refurbishment works, pre-let the four-storey building to Skanska at £30 per sq ft in one of the city's biggest ever office lettings.
Goadsby and CBRE were letting agents.
Skanska, known for its Crossrail and Gherkin projects, was awarded a seven-year Hampshire County Council highways maintenance services contract last year and required a local base urgently.
Winchester-based Gentian director Nick Ekins said: "We have brought one of Winchester's classic buildings back to life after it had lain empty and rundown for eight years. We have helped bring 150 jobs back into the city centre where quality office space is at a premium as demand continues to outstrip supply. Although we had planning consent to convert the building into 27 flats, early knowledge of Skanska's requirements concentrated our minds on Grade A open plan offices and we had to work quickly to achieve the six-month completion target."
Gentian acquired the mid-18th century Georgian town house - with substantial 1970s extension - in 2016 and undertook the £3 million upgrade through specialist sub-contractor Loop Interiors.
The sympathetic refurbishment to restore Trafalgar House to its former glory complied with every conservation regulation and Loop employed traditional building methods where necessary, sometimes with as many as 40 workers on site as speed was of the essence. Refurbishment of the building, overlooking the law courts and Great Hall included the replacement of the roof, windows, lift and the installation of new air conditioning, raised floors, LED lighting, WCs and showers.
Trafalgar House, on Trafalgar Street, was previously home to the county council's social services department before the authority sold it in 2010. Gentian has retained the ground floor office space in the building for its own headquarters and has submitted a planning application for an additional floor to satisfy the city's requirement for more office space.
A decision from the city council's planning department is still awaited.
Long term funding was provided by local relationship bank Handelsbanken.


I used to wonder why the radio only played songs about guys and gals, falling in love, breaking up and making up. My father used to tell me it was because, "Love makes the world go 'round." Well, I've gone round and round a few times, and found out Daddy was mostly right!
When you want to read about people who love their families, friends and neighbors, just turn to your new community magazine, WeatherfordNOW. Weatherford residents will soon receive the premier issue of WeatherfordNOW, the newest addition to a growing publication group known as NOW Magazines. In this full-color magazine, which will be mailed monthly, free of charge, to each physical address in Weatherford, you will find good stories about good people: your friends, your neighbors, maybe even yourself! We are proud to be a part of your community. We are 100 percent supported by our advertisers, and to them, we say, "Thank you." We, in turn, encourage our readers to support our advertisers.
NOW Magazines is an independently owned company started in Corsicana by Publisher Connie Poirier. Under her strong leadership and vision, it has grown to include nine magazines: Corsicana, Weatherford, Burleson, Ennis, Mansfield, Red Oak, Waxahachie and Southwest (which includes Cedar Hill, DeSoto and Duncanville).
We hope you enjoy flipping through these pages and learning more about your community. In this issue, we have featured some of the "movers and shakers" in town, as well as some neighbors you may not yet know. I am excited to learn more about the heart of Weatherford and look forward to meeting you. Feel free to e-mail me or call me — I welcome your feedback and story ideas.


Jalingo – Hundreds of Commuters plying Wukari- Takum Federal highway were on Wednesday stranded as the bridge linking the two towns which has overtime been in deplorable state finally collapsed in the early hours of Wednesday.
Takum which is the home country of the former Minister of Defence and Former Chief of Army Staff, Gen. Theophilus Yakubu Danjuma and Governor of the State, Darius Ishaku has become a source of stress to business men and women plying that road overtime.
An eyewitness, Torsaa Chieve who is a resident of Peva, Chanchanji ward where the bridge is situated while speaking with Vanguard said the bridge collapsed following a heavy rain fall that lasted for several hours.
According to him, residents of the area has overtime cried to government authorities over the deplorable state of the road which has become a death trap.
An Elder in the community, Joseph Kyanden Useh however noted that youths of the area were able to construct a temporary make shift bridge for Commuters to connect Takum.
He said "Today is Peva market and only God knows what would have happened if the bridge collapsed in the day time while people were crossing it to come to the market.
"Peva remains the commercial hub of Taraba especially when it comes to Agricultural business and government must fix the bridge to promote commercial activities here," he said.
In his reaction, Special Adviser to the Governor of Taraba State on New Partnership for Africa's Development (NEPAD), Hon. Dennis Nev who hails from the area called on the federal government to urgently fix the bridge to cushion the sufferings of the people.
According to him, "Takum is central to the economy of the State and they road must not be allowed to be in a bad state for long. It is currently serving both farmers and contractor handling Kashimbila Dam project who are also constructing a power station in Wukari.


Knife Cold Steel 3V Recon Tanto(13QRTK) High quality Cold Steel knives, throwing knives, tactical knives.
Over the last 34 years, Cold Steel has succeeded in establishing the Tanto as a superior blade for combative application. Our pioneering research, development and refinement of this blade shape has proven the value of the "American Tanto" style reinforced point beyond question.Our Recon Tanto continues to redefine the standard for combat knives around the globe. Having seen active military application in numerous conflicts over the last 20 years, it is well on its way to becoming the preferred fixed blade for special military units and even SWAT teams on our own soil. Experience the extraordinary quality of the Japanese VG-1 model, and the new American CPM 3V model - test their distinctive razor sharp edges for yourself and you will see why the Recon Tanto is a knife you can't afford to be without!
I think it's the "perfect knife", the sharpest I have and knowing the hardness of the blade I hope it will remain sharpen for a long time. Very light but strong, perfect to carry and not cumbersome. I'll buy also the Magnum XII version when it will be available.


I've been talking to Arlo about wanting to expand the concert schedule database here on ArloNet. Since the database contains all the dates entered since it was started, you can go back to any year and see where he has been. I'm wanting to add both download links to shows available for download, as well as setlists. Arlo thought it would be cool to see how much of the past we could fill in - going all the way back to Gerdes Folk City in 1961.
So, I'm going to make this a sticky topic, and everyone can help fill in the past info. Pull out your old ticket stubs, and post the info here (date, venue, location, setlist if you have it).
Our current database starts on June 06, 1998 - so if you have any info about shows earlier than this, please post them here!
\Our current database starts on June 06, 1998 - so if you have any info about shows earlier than this, please post them here!
Looking for shows EARLIER than June 6, 1998 - ie: 1961-1998.
Cheryl! Look at ALL the shows you've been to in the past years!!!
I think you should look at that list you've created anytime you feel like moanin' about how unlucky you are not to see arlo at any given time! My goodness, I think only Mrs. G might see arlo as much!
SugarMegs.org has a lot of old bootleg Arlo concerts that people have posted... a couple from Gerdes Folk City and the Bitter End from '66 (one is pretty funny....Arlo is apparently having a show-and-tell with stuff either in his pockets or guitar case...including Excedrin) and several concerts in the '70's with Shenandoah. There's also some more recent concerts, but it's kind of a gold mine if you're looking for old concerts. I've got most of the older ones captured on mini disc...'cuz you never know when a website is gonna disappear.
Do you have ticket stubs for the above dates? Reason I ask is they both conflict with other dates I have. Could the Boston date be the 19th? That fits better. Same with Cambridge, being on the 18th?
April 26th	Grand Valley College	Allendale, MI.
Last edited by adg on Thu Aug 23, 2007 12:32 pm, edited 1 time in total.
If it's a US date, you can leave off the country. Just trying to save myself when it comes to parsing all this data to go into the database.
Good thing I read this.
PS... I'm looking at this stuff.... and how we did these things is unreal. I musta been outta my freaking mind!


原文:You definately look like my old substitute. Mr. Collins. He was awesome!!!!!
原文:Hi. Where in Germany are you?
原文:Oh I love Hawaii!!! Soooo gorgeous.
原文:It was across the street and our streets aren't so big. The police weren't there yet.
原文:I told you I had a shirt like yours.
原文:No his friend found them in his cloths!! So he washed them!! Then put it on his head!!
原文:Oh I've been there way to many times!! Haha and I'm not even 21!


text:
Theodore James "Ted" Petty (Woodbridge (New Jersey), 1 september 1953 - Philadelphia (Pennsylvania), 21 september 2002) was een Amerikaans professioneel worstelaar die vooral bekend was van zijn ringnaam "Flyboy" Rocco Rock.

Hij was vooral bekend van The Public Enemy, een tag team die opgericht werd door hemzelf en Johnny Grunge. Samen wonnen ze verscheidene titels in het tag team-afdeling zoals het ECW World Tag Team Championship en het WCW World Tag Team Championship.

Op 21 september 2002 overleed Petty aan de gevolgen van een hartaanval.

In het worstelen
 Finishers
 Powerbomb, soms door de tafel heen

 Signature moves
 Corner sitout powerbomb
 Diving elbow drop
 Diving leg drop
 Diving splash
 Front dropkick
 Hip toss
 Moonsault
 Somersault senton
 Spinebuster
 Swinging neckbreaker

 Managers
 Tod Gordon
 Jazzy/Jasmin St. Clair
 Kenny Casanova

 Bijnaam
 "Flyboy"

Prestaties
 Cauliflower Alley Club
 Other honoree (1995)

 Eastern Championship Wrestling / Extreme Championship Wrestling
 ECW World Tag Team Championship (4 keer: met Johnny Grunge)
 Hardcore Hall of Fame (2002)

 i-Generation Superstars of Wrestling
 i-Generation Tag Team Championship (2 keer: met Johnny Grunge)

 Independent Wrestling Association Mid-South
 IWA Mid-South Heavyweight Championship (1 keer)

 Main Event Championship Wrestling
 MECW Tag Team Championship (1 keer: met Johnny Grunge)

 National Wrestling Alliance
 Wereld
 NWA World Tag Team Championship (1 keer: met Johnny Grunge)
 Regionaal
 NWA United States Tag Team Championship (1 keer: met Johnny Grunge)

 New England Pro Wrestling Hall of Fame
 Class of 2010

 Superstars of Wrestling
 SOW Tag Team Championship (2 keer: met Johnny Grunge)

 Turnbuckle Championship Wrestling
 TCW Tag Team Championship (1 keer: met Johnny Grunge)

 Tri-State Wrestling Alliance
 TWA Brass Knuckles Championship (1 keer)

 Universal Wrestling Alliance
 UWA Heavyweight Championship (2 keer; eerste kampioen)
 UWA Tag Team Championship (1 keer; eerste kampioen: met Johnny Grunge)

 Universal Wrestling Association
 UWA Light Heavyweight Championship (1 keer)

 World Championship Wrestling
 WCW World Tag Team Championship (1 keer: met Johnny Grunge)

 Andere titels
 NWCW Tag Team Championship (1 keer: met Johnny Grunge)
 WCCA Junior Heavyweight Championship (1 keer)
 WWWC Junior Heavyweight Championship (1 keer)

Zie ook
 The Public Enemy

Externe links
  Profiel op Online World of Wrestling
  Profiel op Cagematch

Amerikaans professioneel worstelaar
Pseudoniem


An innovative application is said to offer a more robust, flexible and far more cost-effective alternative to current journey time solutions and is claimed to be a significant leap forward in the battle to improve safety and reduce congestion.
Developed by Rennicks UK in conjunction with Bluetrace, the system uses Bluetooth and wi-fi technology to monitor and measure traffic movement from the roadside by connecting to devices inside vehicles.
The data is transmitted to a central location to present a clear, real-time picture of the road network and live messages can then be relayed on variable message signs to keep drivers informed. It means congestion and incidents can be identified quickly – improving safety and efficiency across the country and optimising traffic flow. The system, which can be combined with variable message signs, can also be used to improve safety and efficiency in roadwork zones. It will detect the presence and track the movement of highway workers and their vehicles, collecting, analysing and reporting non-personal data to give contractors and repair teams near real-time vision of their entire workforce.


text:
Who can Parsl help?
About Parsl
The Parsl Team
Two-thirds of Americans support cannabis legalization
Alexander Dance
While major politicians continue to describe cannabis as a 'gateway drug', the tide of public opinion is turning. In fact, according to a new Pew Research Center survey, two-thirds of Americans agree that cannabis should be legal across the country.
This isn't the first time where laws have lagged behind public sentiment, it was only recently that the majority of the country favoured same-sex marriage yet the laws forbid it. Although, the law soon became reflective of the public's wants and it was finally legalized. Will the same happen with the legalization of cannabis?
There has been a steady increase in the amount of people who support cannabis legalization whether that be medically or recreationally. The amount of U.S. adults who oppose legalization has fallen from 52% in 2010 to only 32% today.
These numbers are incredibly promising and have left us wondering what the reason behind this sudden rise in support for cannabis legalization is and what prevented their support in the beginning.
We delved into three powerhouses that hold an incredible amount of influence over the masses; the media, religion and the government, to see how these influences originated and how they are beginning to shift.
Media influence
According to a study taken out by The Conversation, it is the media that holds the greatest influence over the public's shift in opinion. According to their study, support for legalization began to increase after the news media began positioning cannabis as a medical issue rather than a political one.
The New York Times was used as a case study looking at cannabis-related articles published between 1983 and 2015. They found that just before the support for cannabis legalization began to increase, there was also a sudden increase in medical related cannabis articles.
Source: https://www.pbs.org/newshour/science/why-so-many-americans-now-support-legalizing-marijuana-in-4-charts
Most cannabis-related articles published within the 80s were in the context of drug trafficking and linked to other schedule I drugs like cocaine and heroin. In the 90s, cannabis-related articles started being framed in the context of the plants medical uses. And by the late 90s, cannabis was rarely discussed in the context of drug trafficking and abuse. During the shift in the media's portrayal of cannabis, the public's support for cannabis legalization began to rise demonstrating a clear correlation between the two.
We may not realize it, but the media holds a particularly strong influence on the views and values of the human population, which can have its pros and cons. Their influence can be used to inform or it can manifest from a place of complete fiction, leaving the masses to think and feel a certain way about a topic based on false claims spread by the media.
These collective opinions entwined with falsified influence from the media can have detrimental effects, like the sorry story of cannabis prohibition. The media spread misleading and often false claims about the plant, influencing society to feel negatively despite the true benefits of cannabis.
It's no secret that many conservative religions are wholly against cannabis, associating it as a sinful indulgence or a tool of the devil. Although cannabis was accepted and widely used within ancient religions, most contemporary religions have developed a very different stance on the plant, and for years condemned the use of it.
Although, this may be changing for the better. A 2016 study by the conservative Christian polling organization Barna Group found that among practising christians, around 34 per cent actually favoured cannabis legalization.
This may not sound like a large amount, but considering the strict and conservative nature of the religion it is quite impressive. Many young people of faith are now beginning to accept and encourage the health benefits of medical cannabis.
Back in 2018, the Church of Jesus Christ of Latter-day Saints asked the Utah Legislature to legalize medical cannabis. Mary Stephens, the church's director of community and government relations stated "we would like to get a solution that will help alleviate pain and suffering for the residents of our state…"
Despite the church's opposition of recreational cannabis, their support of medical cannabis is still incredibly progressive for a religious organization.
Progressive leaders are also attempting to enlighten other Christians as to the health benefits of cannabis. Leaders like California pastor and author, Craig Gross who started Christian Cannabis, a company that wants to educate and engage the faithful on the issue.
The company has a blog and podcast used to enlighten other Christians on the health benefits of cannabis. The brand will also be releasing a line of cannabis products labelled pause, purpose, peace, persevere, praise, pain and people. The products are for the people's "specific, integrative healing and wellness needs." Each product is tailored to help with the specific needs of people whether they're seeking peace, relief from pain, concentration etc. The products come in different forms such as a cbd balm, cannabis-infused mints or pens.
The website asks, "What if Christians were to begin understanding how something like cannabis could be used in beneficial ways to support their lives?"
The negative influence of political propaganda
The Pew Research Center survey discovered that the majority of Millenials (those born between 1981-1997), Generation X (born between 1965-1980) and Baby Boomers (born between 1946-1964) supported legalization of cannabis use.
Although, members of the Silent Generation (born between 1928-1945) were the least supportive, with 64 percent opposing cannabis legalization.
When looking at the government's efforts to demonize cannabis during the Silent Generations upbringing, it is easy to understand these figures.
In fact, in the context of cannabis prohibition calling them the Reefer Madness Generation would be more fitting considering the heavy influence they received from political propaganda. When the film Reefer Madness was released in 1936, it fuelled the hysteria spread by the government around cannabis.
The film centres around innocent high school students who are lured into trying cannabis. The effects of it apparently result in a hit-and-run accident, manslaughter, suicide, attempted rape, hallucinations and a descent into madness.
The fictional film supported the word of the government and continued to influence the generation despite being based on a myriad of lies.
It is promising to see that American's stance on cannabis legalization is beginning to change for the better. Whether it is the media, a shift in religious views, or a decrease in negative political propaganda; Americans are finally beginning to accept and embrace the benefits of cannabis. As they say, the proof is in the pudding (or the Pew Research Center Survey).
Author: Alexander Dance
Alexander has worked in marketing and content creation for 6 years with a strong focus in the digital space. He has a strong grounding across all marketing channels with a specific focus in SEO, copywriting, video, conversion optimisation and design. He is passionate about evidence-based marketing.
Cannabis Compliance Complications in ...
The Cannabis Catch Up (November 29 &...
Every week there is a lot that goes on in the world of cannabis, and sometimes it can be a little hard to k...
Two-thirds of Americans support canna...
While major politicians continue to describe cannabis as a 'gateway drug', the tide of public opinion is tu...
Why desperate Veterans can't access m...
Cannabis, Regulation
Research from the British Columbia Centre on Substance Use (BCCSU) and University of British Columbia deter...
The Cannabis Catch Up (November 22-28)
Copyright © 2021 Parsl
Download our whitepaper
Melbourne Office 102/1 Bowen Crescent Melbourne, 3004, VIC. Australia


Note: Review Per Lead The U.S. Marine Corps operates the Marine Corp Mountain Warefare Training Center Bridgeport in Mono County, CA on National Forest System lands managed by the Humboldt-Toiyable National Forest, Bridgeport Ranger District. The Proposed Action is to establish Special Use Airspace consisting of two Military Operations Areas in airspace located above and adjacent to MCMWTC. The purpose of the PA is to improve flight safety for all pilots (civilian, commercial, and military) and support existing military training programs by improving airspace management and coordination in the airspace above and adjacent to MCMWTC. The PA is needed to address training delays and flight safety issues (e.g., near-midair collisions) that have occurred when non-participating aircraft have entered the airspace while MCMWTC training activities were being conducted.